Get the Stockscreener App
2.50
0.00%
0.00
Pre-market:
2.50
Anavex Life Sciences Corp stock is traded at $2.50, with a volume of 932.13K.
It is up +0.00% in the last 24 hours and down -14.09% over the past month.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
See More
Previous Close:
$2.50
Open:
$2.55
24h Volume:
932.13K
Relative Volume:
0.68
Market Cap:
$231.68M
Revenue:
-
Net Income/Loss:
$-39.95M
P/E Ratio:
-5.3775
EPS:
-0.4649
Net Cash Flow:
$-34.08M
1W Performance:
-4.58%
1M Performance:
-14.09%
6M Performance:
-39.61%
1Y Performance:
-68.87%
1-Day Range:
$2.47
$2.58
1-Week Range:
$2.41
$2.7299
52-Week Range:
$2.41
$13.99
Anavex Life Sciences Corp Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corp
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corp
|
2.50 | 231.68M | 0 | -39.95M | -34.08M | -0.4649 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anavex Life Sciences Corp Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corp Stock (AVXL) Latest News
Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health - MSN
Anavex slips after CEO transition - MSN
Anavex appoints interim CEO following leadership change - Investing.com
AVXL Stock Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
AVXL Technical Analysis & Stock Price Forecast - Intellectia AI
AVXL Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Clinical Progress - newsline.com
AVXL News | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
AVXL Stock Price, Quote & Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
MSN Money - MSN
Penny Stocks To Watch In May 2026 - Sahm
AVXL Q1 2026 Earnings: Narrowed Loss Beats Estimates as Clinical Pipeline AdvancesEarnings Manipulation Risk - newsline.com
AVXL Technical Analysis | Trend, Signals & Chart Patterns | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Anavex Life Sciences (AVXL) Edges Lower, Hovering Near Key SupportMFI Divergence - newsline.com
Anavex Faces Nasdaq Compliance Pressure Over Late Filing - The Globe and Mail
Anavex Life Sciences (AVXL) Faces Nasdaq Compliance Challenge - GuruFocus
Anavex (AVXL) Faces Nasdaq Notification Due to Filing Delay - GuruFocus
Anavex Life Sciences receives Nasdaq delisting warning - Investing.com UK
Anavex Life Sciences receives Nasdaq delisting warning By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
Anavex Life Sciences receives expected Nasdaq delinquency notification - marketscreener.com
Anavex Life Sciences Received Notice of Noncompliance - TradingView
Nasdaq warns Anavex (Nasdaq: AVXL) over delayed quarterly filing - Stock Titan
Anavex Life Sciences Corp. Receives Delinquency Notification From Nasdaq for Non-Compliance With Listing Rule - Moomoo
Anavex Life Sciences Corp. Receives Delinquency Notification from Nasdaq for Non-Compliance with Listing Rule - Quiver Quantitative
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification - Anavex Life Sciences
Anavex Life Sciences stock crushed as European Alzheimer's drug filing pulled after EMA pushback - MSN
Anavex Life Sciences Announces COO Departure Amid Restructuring - The Globe and Mail
Anavex (AVXL) COO exits amid reorganization; option grant largely forfeited - Stock Titan
Anavex (AVXL) interim CEO discloses detailed stock option grants - Stock Titan
Anavex withdraws EU approval filing for Alzheimer’s therapy - MSN
Anavex Stock Just Logged Its Worst Selloff In 2 Years — What Does EMA’s Oral Explanation Week Mean For Its Alzheimer’s Drug? - MSN
AVXL stock tanks after Anavex withdraws EU bid for Alzheimer's drug - MSN
Anavex Delays Quarterly Filing Amid CEO Shake-Up - The Globe and Mail
TradingKey - TradingKey
Anavex Life Sciences (AVXL) Delays Quarterly Report Submission - GuruFocus
AVXL SEC FilingsAnavex Life Scie 10-K, 10-Q, 8-K Forms - Stock Titan
Anavex Life Sciences (NASDAQ: AVXL) delays 10-Q after CEO termination - Stock Titan
Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring A 605% Upside Potential - DirectorsTalk Interviews
Biopharma veteran takes her CEO Cue—Chutes & Ladders - Fierce Biotech
Anavex (AVXL) Appoints Interim CEO Amid Leadership Change - GuruFocus
Anavex Life Sciences Names Interim CEO Amid Leadership Shift - The Globe and Mail
Number of shareholders of Anavex Life Sciences Corp. – FWB:12X1 - TradingView
Anavex Life Sciences Appoints Terrie Kellmeyer as Interim CEO Following Christopher Missling’s Departure - Minichart
CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus - Yahoo Finance
Anavex stock slips after CEO transition (AVXL:NASDAQ) - Seeking Alpha
Anavex appoints interim CEO following leadership change By Investing.com - Investing.com India
Anavex Life Sciences Corp Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):